TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients aged \>=18 years~* Patients with Non Valvular Atrial Fibrillation~* Patient presenting with:~An Acute Coronary Syndrome (ACS) (ST elevation myocardial infarction (STEMI), NonSTEMI \[NSTEMI\] or unstable angina \[UA\]) that was successfully treated by PCI and stenting (either Bare Metal Stent (BMS) or Drug Eluting Stent) Or Stable Coronary Artery Disease with at least one lesion eligible for PCI that was successfully treated by elective PCI and stenting (either BMS or DES)~* The patient must be able to give informed consent in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and local legislation and/or regulations.~Exclusion criteria:~* Patients with a mechanical or biological heart valve prosthesis~* Cardiogenic shock during current hospitalisation~* Stroke within 1 month prior to screening visit~* Patients who have had major surgery within the month prior to screening~* Gastrointestinal haemorrhage within one month prior to screening, unless, in the opinion of the Investigator, the cause has been permanently eliminated~* Major bleeding episode including life-threatening bleeding episode in one month prior to screening visit~* Anaemia (haemoglobin \<10g/dL) or thrombocytopenia including heparin-induced thrombocytopenia (platelet count \<100 x 109/L) at screening~* Severe renal impairment (estimated Creatinine Clearance (CrCl) calculated by Cockcroft-Gault equation) \<30mL/min at screening~* Active liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabigatran Etexilate 110mg (Type: EXPERIMENTAL): Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
- Dabigatran Etexilate 150mg (Type: EXPERIMENTAL): Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
- Warfarin (Type: ACTIVE_COMPARATOR): Warfarin doses to maintain INR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic Manipulation in Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Optimally-medicated idiopathic dilated cardiomyopathy~* Symptomatic ( NYHA IIb-III)~* Impaired left ventricular systolic function (EF \< 40%)~Exclusion Criteria:~* Abnormal liver function tests (defined as above twice the upper limit of normal (ULN))~* Concomitant use of Amiodarone , Quinidine , Haloperidol or Selective serotonin (5HT) uptake inhibitors such as Fluoxetine and Paroxetine which may inhibit the CYP2D6 enzyme.~* Pre-existing evidence of peripheral neuropathy.~* Women of childbearing potential.~* Patients with implantable cardiac devices (or any other contraindication to MRI).~* Obesity ( BMI \> 32)~* Obstructive sleep apnea syndrome~* Patients with known hypersensitivity to perhexiline~* Patients with impaired renal function (Creatinine \> 250 µmol/L)~* Valvular heart disease defined as more than moderate valvular stenosis or regurgitation.~* Atrial Fibrillation

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Perhexiline (Type: EXPERIMENTAL): perhexiline 100mg bd for 1 month duration
- Placebo (Type: PLACEBO_COMPARATOR): placebo one tablet bd for 1 month duration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fully vaccinated per-protocol (4 doses of vaccine given at 2, 4, 6, and 12-15 months of age) subjects enrolled in the Prevnar arm of Study D118-P8, OR~* Fully vaccinated per-protocol subjects from the control arm of the same study that did not receive Prevnar after the close of Study D118-P8, or at any time following the study, AND~* Still enrolled in NCKP health plan.~* Subjects included in either group above must be in good health as determined by medical history, physical examination, and clinical judgment.~Exclusion Criteria:~* Previous receipt of pneumococcal polysaccharide vaccine.~* History of documented recurrent pneumococcal otitis media or any occurence of pneumonia within past 12 months~* History of documented invasive pneumococcal disease (defined as a positive culture of S. pneumoniae from a normally sterile body site).~* Known or suspected disease or dysfunction of the immune system, including:~* HIV infection~* Malignancy~* Receipt of immunosuppressive therapy~* Sickle cell hemoglobinopathy~* Concomitant vaccination during the study period.~* Known hypersensitivity to any component of Prevnar.~* Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of, the study, or could preclude the evaluation of the subject's response.~* Receipt of immune globulin within the past 3 months.~* Positive pregnancy test for menarchal female subjects.~* Females who are breastfeeding.~* For control subjects, previous receipt of Prevnar at any time.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Subjects received Prevnar in study D118-P8
- 2 (Type: EXPERIMENTAL): Subjects received MnCC in study D118-P8

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Wise App Trial for Improving Health Outcomes in PLWH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of HIV~* Report past 30 days adherence of 80% or less as measured using the Visual Analogue Scale (VAS), or have a viral load of over 400 copies/mL~* Be able to communicate and read in English or Spanish~* Live in the US~* Have a smartphone~* Be taking ART medications~Exclusion Criteria:~* Participation in any other mobile app study for PLWH, including text messaging studies~* Diagnosis of a clinical problem that would preclude someone from using a smartphone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: SHAM_COMPARATOR): WiseApp that delivers fitness reminders
- Intervention (Type: EXPERIMENTAL): WiseApp that delivers medication adherence reminders

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 12-week Efficacy of Indacaterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] Guidelines, 2008) and:~  * Smoking history of at least 10 pack-years~ * Post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 80% and ≥ 30% of the predicted normal value~ * Post-bronchodilator FEV1/FVC (forced vital capacity) \< 70%~Exclusion criteria:~* Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to screening~* Patients who have had a respiratory tract infection within 6 weeks prior to screening~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular co-morbid conditions Other protocol-defined inclusion/exclusion criteria applied to the study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 75 μg (Type: EXPERIMENTAL): Patients inhaled indacaterol 75 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
- Placebo to indacaterol (Type: PLACEBO_COMPARATOR): Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medical screening.~* Female and male subjects aged 8-16 years and 11 months, with clinical anorexia nervosa and / or reference to the diagnostic criteria of DSM-IV (1) before or at early puberty (Tanner stage 1 or 2) and with a prolonged Catch-Down for at least 18 months (HV ≤ 2 cm / year), with bone age ≤ 12 years in girls and ≤14 years in boys.~* Anorexia nervosa diagnosed at least 1 year before the study~* Growth velocity documented for at least 18 months before inclusion~* As with any child with a severe Catch-Down an assessment of GH secretion must be performed before inclusion (in the context of care) in the trial, which is not conditioned by the GH peak value : GH value of \<20 miu / L will lead to the production of a brain MRI (in the context of care) that have to be normal (normal hypothalamic-pituitary axis and absence of tumor pathology) to allow Inclusion of the patient.~* Normal glucose tolerance~* Stable metabolic state with of weight gain of at least 10% of body weight from the time the body mass index was the lowest in relation to the occurrence of the disease and normal blood electrolytes (no hypokalemia) .~* Subjects whose holders have signed parental consent~* Subjects whose holders of parental authority are affiliated to a social security scheme~* CMU (CMU universal medical coverage).~Exclusion Criteria:~* Subjects in the mid-puberty (Tanner stage 3 or 4) or with menarche.~* Subjects with a chromosomal abnormality or other chronic disease associated chronic requiring long-term treatment.~* Impaired glucose tolerance or diabetes.~* Inability of the patient or the medical team to ensure the progress and monitoring under the protocol.~* Participation in another trial.~* Bradycardia ≤ 50 bpm.~* Children whose holders of parental authority are not beneficiaries of social security~* Contra-indication to SOMATROPINE

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 203 Months
- Healthy Volunteers: f

Study Arms:
- SOMATROPINE* : Norditropine® simplexx® (Type: ACTIVE_COMPARATOR): SOMATROPINE\* : Norditropine® simplexx®
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who presented or were admitted to hospital with:~  1. Signs and symptoms of AMI~ 2. Were able to randomize within 12 hours of symptom onset; and-~ 3. Had definite ECG changes indicating STEMI: persistent ST-elevation (≥0.2mV in two contiguous precordial leads, or ≥0.1mV in at least two limb leads), or new left bundle branch block, or ECG changes indicating true posterior MI.~* Written informed consent~* Able to be randomized within 24 hours of symptom onset~Exclusion Criteria:~* Age \<21 years.~* Was currently receiving an oral anticoagulant agent with an INR \>1.8.~* Had any contraindication to anticoagulation therapy such as high risk of bleeding or active bleeding.~* Had hemorrhagic stroke within the last 12 months.~* Had an indication for anticoagulation other than ACS.~* Pregnant women or women of child-bearing potential who were not using an effective method of contraception.~* Had a co-morbid condition with a life-expectancy \<6 months.~* Previous enrollment in one of the fondaparinux ACS trials.~* Participation in another pharmacotherapeutic study within the prior 30 days or was currently receiving an experimental pharmacological agent.~* Had a known allergy to heparin or fondaparinux.~* Had severe renal insufficiency (i.e. serum creatinine ≥3mg/dL or ≥265μmol/L).~* Had \>5000IU UFH administered prior to randomization.~* Had LMWH administered prior to randomization.~* Subject had pre-randomization revascularization (PCI) for the index event.~* Subject had pre-randomization rescue PCI.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fondaparinux - UFH not indicated (Type: EXPERIMENTAL): Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge
- Control - UFH not indicated (Type: PLACEBO_COMPARATOR): Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
- Fondaparinux - UFH indicated (Type: EXPERIMENTAL): Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion
- Control - unfractionated heparin (Type: ACTIVE_COMPARATOR): Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Persistent Viremia (Virus in Blood) in Chronic Hepatitis B Subjects Already Receiving Adefovir Dipivoxil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 through 69 years of age, inclusive~* Chronic HBV infection, defined as positive serum HBsAg for at least 6 months~* Active chronic HBV infection with all the following:~  1. Currently treated with adefovir dipivoxil 10 mg QD (for at least 24 weeks but not more than 96 weeks)~ 2. HBeAg positive or negative at screening~ 3. Plasma HBV DNA \>/= 1000 copies/mL at screening (irrespective of HBeAg status)~ 4. Serum ALT less than 10 times the upper limit of normal (ULN)~ 5. Calculated creatinine clearance of at least 70 mL/min using the Cockcroft-Gault formula~ 6. Hemoglobin at least 8 g/dL~ 7. Neutrophils at least 1,000 /mm3~* Nucleoside naive except for lamivudine (\>/= 12 weeks of therapy)~* Negative serum beta human chorionic gonadotropin~* Compliant with adefovir dipivoxil~* Willing and able to provide written informed consent~Exclusion Criteria:~* Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study~* Male or females of reproductive potential who are unwilling to use an effective method of contraceptive while enrolled in the study. For males, condoms should be used and for females, a barrier contraception method should be used~* Decompensated liver disease defined as conjugated bilirubin greater than 1.5 times ULN, prothrombin time (PT) greater than 1.5 times ULN, platelets less than 75,000/mm3, serum albumin less than 3.0 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage)~* Prior use of tenofovir DF or entecavir~* Received treatment with interferon or pegylated interferon within 6 months of the screening visit~* Evidence of hepatocellular carcinoma (HCC); for example, alpha-fetoprotein greater than 50 ng/mL or by any other standard of care measure.~* Co-infection with HCV (based on serology), human immunodeficiency virus (HIV), or hepatitis delta virus (HDV)~* Significant renal, cardiovascular, pulmonary, or neurological disease.~* Received solid organ or bone marrow transplantation.~* Is currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion~* Has proximal tubulopathy~* Known hypersensitivity to the study drugs (tenofovir DF or emtricitabine/tenofovir DF), the metabolites (tenofovir or emtricitabine) or formulation excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): TDF
- 2 (Type: EXPERIMENTAL): FTC/TDF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Participants who are susceptible to cold sores that reactivate when exposed to ultraviolet (UV) light

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Test patch (Type: EXPERIMENTAL): Patch containing acyclovir applied to cold sore
- Placebo patch (Type: PLACEBO_COMPARATOR): Patch without acyclovir applied to cold sore

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary PAP (new or chronic) with presence of anti-GM-CSF antibody~* Moderately symptomatic disease with PaO2 \<70 on room air and on less than 6 L/min oxygen~* Able to give written informed consent and comply with the requirements of the study~* Adequate renal and liver function~* Negative serum pregnancy test (for women of child bearing age) and on acceptable birth control during and after study completion~Exclusion Criteria:~* Severe PAP and requires in-patient care and more urgent therapy with bilateral whole lung lavage~* Treatment with any investigational agent within 4 weeks of screening~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies~* History of HIV, recurrent significant infection or recurrent bacterial infections~* Known active bacterial, viral, fungal, mycobacterial, or other infection~* Ongoing use of high dose steroids (\>10mg/day) or unstable steroid dose~* Significant cardiac or pulmonary disease or blood disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A current clinical diagnosis of COPD with COPD symptoms for more than 2 years~* Current smoker or smoking history of 10 or more pack years (1 pack year = 20 cigarettes smoked per day for one year)~* A history of at least 1 COPD exacerbations requiring a course of steroids and/or antibiotics within 1-12 months before the first visit~Exclusion Criteria:~* A history of asthma at or after 18 years of age~* A history of allergic rhinitis at or after 18 years of age~* Subjects taking oral steroids~* Any significant disease or disorder that may jeopardize a subject's safety

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sickle Cell Disease~* Ages 3 years - 21 years~Exclusion Criteria for Enrollment:~* Pregnancy~* Known allergy to Fentanyl~* Usage of daily home opiates~Exclusion Criteria at presentation in ED with a painful crisis:~* Wong Baker FACES Pain Score \<6~* Systolic blood pressure \< 5 percentile for age~* Oxygen saturation \<92% on room air~* Temperature \> 102°F~* Respiratory distress~* Priapism~* Isolated abdominal pain~* Isolated headache~* New neurological symptoms~* Severe rhinorrhea or epistaxis~* History of trauma~* Pregnancy

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Intranasal Saline (Type: PLACEBO_COMPARATOR): None
- Intranasal Fentnayl (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete